The microplates market is set to reach US$ 1488 million by 2033 from US$ 993.51 million in 2024 at a compound annual growth rate (CAGR) of 4.2% during the forecast period from 2025 to 2033. Microplate technologies has been increasingly applied across variety of applications within the field of biotechnology research over the past couple of decades. Researchers are of the opinion that the equipment plays an essential part in the upkeep of productive and accurate data outcomes, as well as in the overall performance of the study. The nature of analytical tests and assays has changed significantly over the course of the years, and a trend toward volume minimization for the purpose of performing drug screening can currently be observed in the market. The design of microplates is evolving as a direct result of this factor. To meet the ever-changing needs of researchers, a significant quantity of microplates, each with its own kind, color, well design, and material, among other characteristics, is necessary. The goal of one of the many projects being pursued by manufacturers is to cut down on the quantity of reagents and chemicals needed for research while maintaining the same level of quality in both the process and the results.
Devices belonging to the microplate and microplate instrumentation categories are an essential part of the cell culture process as well as other types of research. In the beginning, these devices were exclusively utilized in research settings, such as laboratories. However, currently there has been increased use in the field of disease diagnosis, which led to their presence in diagnostic laboratories as well as hospitals. As a result, microplates are used in the process of drug discovery and development, in addition to comprehending the cellular reactions in any type of research. As a result, microplates are necessary components in a variety of testing methods and production processes. The need for microplates in research settings is steadily increasing as a direct result of their capacity to perform simultaneous analysis on a number of different samples.
Increasing Demand for ELISA Testing
The Enzyme-Linked Immunosorbent Assay, more often known as ELISA, is a type of immunoassay that may recognize hormones, antibodies, peptides, and proteins. The ELISA assay has applications in biotechnology medicine as a diagnostic tool that detects a color change to identify a target substance and estimates its quantity in the test sample. This can be done by comparing the color of the sample to a standard. Infection with the Human Immunodeficiency Virus (HIV), tests to determine whether or not a woman is pregnant, and the detection of cytokines, soluble proteins, and other biomarkers are typical diagnostic applications of ELISA. The immunoassay makes use of a wide variety of antigen-antibody combinations, one of which is enzyme-labeled (either the antigen or the antibody), and measures the activity of the enzyme.
High Maintenance Cost Associated with Target Validation and Process Automation Pertaining to High Throughput Screening
Target validation and process automation are the two issues that pharmaceutical companies run into most frequently during the high throughput screening stages of the development process. During the main screening, the greatest obstacle that researchers must overcome is determining whether or not they are working with the appropriate drug. If the target identification is revealed to be incorrect at the conclusion of the test, this frequently leads to a wasteful endeavor that costs money due to the loss of microplates, chemicals, and working hours. Accidents caused by humans, such as the loss of micro titers of useful biological reagents, spilling, and the addition of impurities while handling microplates, have led to erroneous results, which have frequently led to validation issues of designed protocols pertaining to micro assays during the secondary screening stage. Human errors, such as the loss of micro titers of useful biological reagents, spilling, and the addition of high throughput screening of novel drugs, the automation of microplate handling to reduce human error is resulting in the loss of huge funds to design tools and software to ensure smooth operations and desired results. This is a direct result of the automation of microplate handling to reduce human error.
Technological Compatibility and Standardization
Technological Compatibility and Standardization in the microplate market is a substantial one. Microplates are central to high-throughput assays and screenings, making them integral in research and diagnostic laboratories. Ensuring they seamlessly integrate with various laboratory instruments, such as microplate readers, washers, and automated liquid handling systems, is crucial. The diversity of equipment from different manufacturers each with their unique specifications, exacerbates the challenge. Inconsistencies or lack of standardization in microplate dimensions, well depth, and shape can lead to significant operational hurdles. Labs may encounter difficulties in achieving efficient and reliable processing if the microplates used are not universally compatible with their existing equipment setup.
Increasing Investment in The Biopharmaceutical Industry in Emerging Economies
Manufacturers of microplates often view emerging economies as lucrative destinations to sell their products. These nations are home to significant portions of the target population. The key biopharmaceutical players who are experiencing patent expirations, stagnation of established markets, and rising regulatory hurdles can be attracted to your company for a number of reasons, but the most important ones are improving lifespan and expanding profitability. These markets are extremely important to the continued expansion of top medical device firms that manufacture microplates, and they play an important part in that expansion. Developing countries are home to a sizeable portion of the world's population, and a large fraction of that population is actively working to improve their healthcare systems and achieve better treatment outcomes.
Market Segmentation By Type
With respect to the type of microplates, the 384-well microplates were the largest market in 2024 contributing to over 40.1% of the revenue share. Their capacity to carry out miniature gene transfer experiments is the defining characteristic that contributes most significantly to their preeminence. This assists in minimizing the cost that is paid throughout the procedures of the experiment, and at the same time, it gives a high throughput during the transfection of immortalized and primary cells in contrast to other microplates.
Market Segmentation By Application
Research techniques such as the discovery of disease targets, drug assessment, and gene characterization extensively apply cell culture as a fundamental and standard methodology. The nature of this process is complex; nonetheless, it is significantly easier to access, less expensive, and comparatively time and labor efficient than in vivo research approaches, and it also has fewer ethical considerations. Cell culture can be carried out at a large scale with the assistance of huge bioreactors, or it can be carried out at a small size with the assistance of multiwall plates. The use of microplates in cell culture models is gaining popularity because these models enable the analysis of a multitude of dynamic variables, which in turn enables increased experiment output while simultaneously lowering the amount of time and money required for the experiment.
Market Segmentation By Geography
North America currently held the largest revenue share in the global microplates market in 2024 by contributing to about 30.1%. The rising prevalence of chronic and acute disease conditions in North America, as well as the widespread availability of healthcare facilities for prompt diagnosis and treatment are the key drivers boosting the market revenues in this region. This region is also expected to maintain its leading position throughout the duration of the forecast period. Another factor contributing to the expansion of the market in this region is the increasing trend of automation in biolaboratories. It is anticipated that the Asia Pacific region would experience significant market expansion over the course of the projected period. This occurs as a result of the rapid growth of the infrastructure of healthcare and the increased investments in research and development of biotechnology and medicines. The growing outsourcing of biotechnology contract research processes is also among the key drivers.
M&A Remains One of the Most Significant Market Strategies Deployed by Top Companies
The global microplates market is characterized by some notable players and hence, the market is quite fierce in terms of competition. Key players profiled in the report include Corning Incorporated, Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Eppendorf AG, Porvair Sciences Limited, Berthold Technologies GmbH & Co. KG, Greiner Bio One International GmbH, Avantor, Inc., Becton, Dickison and Company, QIAGEN N.V., SPL Life Sciences, Hirschmann Laborgerate GmbH & Co. KG, among others. Though new product development has remained the key strategy in the previous 5 years, the trend has changed significantly. Tier 1 companies are focusing on umbrella strategies which include mergers and acquisitions focused on holistic development rather than product-oriented strategies. For example, only Thermo Fischer has performed over 4 relevant acquisitions during the period of 2020 to 2021. In Sep 2021 Avantor, Inc announced that it has entered into a definitive agreement to acquire the Masterflex bioprocessing business and related assets (collectively "Masterflex") of Antylia Scientific, a privately held, portfolio company of investment firms GTCR and Golden Gate Capital. In June 2021, Avantor also completed the acquisition of Ritter GmbH and its AffiliatesThe acquisition aims at enhancing the company’s position in the field of molecular diagnostics as a whole. Though COVID-19 has impacted the market largely with respect to mergers and acquisitions, Tier 1 companies have focused on this strategy.
Historical & Forecast Period
This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Microplates market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2023-2033 |
| Base Year | 2024 |
| Forecast Period | 2025-2033 |
| Historical Year | 2023 |
| Unit | USD Million |
| Segmentation | |
Type
| |
Application
| |
Base Material
| |
Pigmentation
| |
Well Design
| |
|
Region Segment (2023-2033; US$ Million)
|
Key questions answered in this report
